8 completed, 3 unknown, 2 terminated. 13 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 8, Unknown 3, Terminated 2 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 2 | Unknown 2 |
Follow Hyponatremia: new trials by email Literature Review of Hyponatremia trials Research Report on Hyponatremia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cicletanine in Hypertension With Diabetes: Added Magnesium Preserves Potassium and Sodium Cicletanine + magnesium, Cicletanine - Arterial Hypertension, Diabetes | Phase 1 / Phase 2 | Unknown | Navitas Pharma | 24 | 2022-06-01 | 2021-09-05 |
| Urea for Chronic Hyponatremia Urea - Hyponatremia, Inappropriate ADH Syndrome | Phase 2 | Terminated | Helbert Rondon Berrios, MD, MS | 2 | 2021-12-28 | 2024-05-20 |
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study Empagliflozin 25mg, Placebo - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 17 | 2017-12-15 | 2021-12-13 |
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study Empagliflozin, Placebo - SIADH | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 88 | 2016-09-05 | 2019-06-13 |
| Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl, Placebo P-Tablet - Inappropriate ADH Syndrome | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 15 | 2016-03-01 | 2016-08-10 |
| Safety and Feasibility of Hypertonic Saline Solution After Aneurysmal Subarachnoid Hemorrhage: HTS 3%, Standard fluid management - Subarachnoid Hemorrhage, Cerebral Vasospasm | Phase 1 / Phase 2 | Unknown | Thomas Jefferson University | 50 | 2015-01-01 | 2016-02-11 |
| Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Tolvaptan, Placebo - Non-hypovolemic Non-acute Hyponatremia | Phase 2 / Phase 3 | Unknown | Jiangsu HengRui Medicine Co., Ltd. | 240 | 2012-01-01 | 2012-01-11 |
| Tolvaptan for In-hospital Hyponatremia Tolvaptan, Standard therapy - Hyponatremia | Phase 2 | Terminated | Mario Negri Institute for Pharmacological Research | 3 | 2011-06-01 | 2016-12-15 |
| Efficacy Study of VA106483 in Males With Nocturia. VA106483 - Nocturia | Phase 2 | Completed | Vantia Ltd | 152 | 2009-12-01 | 2014-06-20 |
| A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia Tolvaptan, Placebo - Hypovolemic Hyponatremia | Phase 2 | Completed | Otsuka Beijing Research Institute | 241 | 2008-05-01 | 2025-03-25 |
| Hypertonic Saline Solution in Heart Failure NaCl 7,5% (Hypertonic Saline Solution), NaCl 0,9% - Heart Failure, Renal Failure | Phase 2 | Completed | University of Sao Paulo | 34 | 2008-02-01 | 2014-06-10 |
| Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites satavaptan (SR121463B) - Ascites, Liver Cirrhosis | Phase 2 | Completed | Sanofi | 110 | 2004-04-01 | 2009-01-12 |
| Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion satavaptan (SR121463B) - Syndrome of Inappropriate ADH (SIADH) Secretion, Hyponatremia | Phase 2 | Completed | Sanofi | 35 | 2001-06-01 | 2008-06-17 |
Inappropriate ADH Syndrome (6) · Ascites (1) · Diabetes Insipidus (1) · Diabetes Mellitus (1) · Heart Failure (1) · Hypertension (1) · Hypokalemia (1) · Liver Cirrhosis (1) · Metabolic Diseases (1) · Nocturia (1) · Renal Insufficiency (1) · Subarachnoid Hemorrhage (1) · Vasospasm, Intracranial (1)
Nutritional and Metabolic Diseases (13) · Water-Electrolyte Imbalance (13) · Metabolic Diseases (12) · Brain Diseases (7) · Central Nervous System Diseases (7) · Endocrine System Diseases (7) · Nervous System Diseases (7) · Hypothalamic Diseases (6) · Pituitary Diseases (6) · Cardiovascular Diseases (3) · Pathological Conditions, Signs and Symptoms (3) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2)
Tolvaptan (3) · empagliflozin (3) · satavaptan (2) · 5-(3-hydroxybenzoyl)-2-thiophenesulfonamide (1) · Magnesium (1) · Saline Solution, Hypertonic (1) · Standard of Care (1) · Tablets (1) · Urea (1) · cicletanine (1)
University Hospital, Basel, Switzerland (3) · Sanofi (2) · Helbert Rondon Berrios, MD, MS (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Mario Negri Institute for Pharmacological Research (1) · Navitas Pharma (1) · Otsuka Beijing Research Institute (1) · Thomas Jefferson University (1) · University of Sao Paulo (1) · Vantia Ltd (1)
United States (4) · Switzerland (3) · Belgium (2) · China (2) · France (2) · Germany (2) · Hungary (2) · Italy (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Croatia (1) · Czechia (1) · Romania (1)
Aris Nikas (1) · Bruce Rankin (1) · Chris Ng (1) · David Beccia (1) · Earl Martin (1) · Edimar A Bocchi, Professor (1) · Elizabeth Houser (1) · Evan Goldfischer (1) · Feng Gu (1) · H. David Mitcheson (1) · Helbert Rondon Berrios, MD. MS (1) · Howard Hezmall (1) · Jidong Jia (1) · Joseph Parkhurst (1)
PMID 17992382, PMID 18508290, PMID 22243938, PMID 24906029, PMID 30180806, PMID 34412521, PMID 36396331, PMID 37098131, PMID 42522233
2015 (1), 2017 (1), R21DK122023 (1)